Activating PP2A with FTY720 (Fingolimod/ Fingolimod Hydrochloride, a sphingosine-1-phosphate (S1P) antagonist) suppresses tissue inflammation and serum IgE levels in the ovalbumin-induced asthma mouse model, which is further enhanced when combined with proteasome inhibitor bortezomib, which suppresses CIP2A expression by an unknown mechanism [65]. This evidence concerns the gene PTPA and asthma.